Tigecycline

Y. Vivian Tsai, Pharm.D., Kathryn Dzintars, Pharm.D., BCPS

INDICATIONS

FDA

  • Complicated skin and skin structure infections
    • Author’s comment: not a first-line agent.
  • Complicated intra-abdominal infections
    • Author’s comment: not a first-line agent. Avoid in bacteremia.
  • Community-acquired bacterial pneumonia
    • Author’s comment: not a first-line agent.
  • Monitoring:
    • Due to risk of hypofibrinogenemia/coagulopathy, recommendation to obtain baseline and periodic coagulation parameters, including fibrinogen.

NON-FDA APPROVED USES

  • Nontuberculous mycobacterial infection due to rapidly growing organisms (e.g. M. abscessus), as part of a combination regimen
  • Infections due to MDR gram-negative organisms, including CRE and carbapenem-resistant A. baumannii
    • Author’s comment: Not a first-line agent. Avoid in bacteremia and urinary tract infection.
  • Infections due to VRE-faecium
    • Author’s comment: Not a first-line agent. Avoid in bacteremia and urinary tract infection.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: November 7, 2026